Combretastatin A4 is primarily used in medical research and treatment, particularly in the field of oncology. It functions as a vascular disrupting agent, targeting and collapsing the blood vessels that supply tumors. This action starves the tumor of oxygen and nutrients, leading to its shrinkage. It is often studied in combination with other cancer therapies, such as chemotherapy or radiation, to enhance their effectiveness. Additionally, it is being explored for its potential in treating age-related macular degeneration by inhibiting abnormal blood vessel growth in the eye. Its unique mechanism makes it a promising candidate for further development in cancer and other vascular-related diseases.